Genesis-Proudi merger brings algae into mainstream pet food
Bottom line
Australian microalgae producer Genesis Group has merged with Brisbane-based pet food manufacturer Proudi, a deal that brings Genesis directly into companion animal nutrition and gives its chlorella ingredient a faster path into mainstream retail. Reporting on August 25, 2026, said the Queensland producer will use Proudi’s existing distribution through Coles, Petbarn, and Pet Circle, while progressively adding chlorella across more of Proudi’s portfolio. Trade reporting valued the deal at about A$38 million, and said Proudi founder Dennis King will join the Genesis board while CEO Eric Chen continues to lead the combined group. (efeedlink.com)
Why it matters: For veterinary professionals, the merger is another sign that algae-derived ingredients are moving from niche supplements into scaled commercial pet food. That could mean more diets marketed around sustainability, functional nutrition, and gut or immune support. But the evidence base is still developing: recent reviews say microalgae such as chlorella are gaining attention for protein, omega-3s, micronutrients, and bioactive compounds, while also noting that companion-animal data remain limited, palatability can be a constraint, and cat-specific feeding studies are still a key gap. (sciencedirect.com)
What to watch: Watch for product launches through Coles and other retail channels, formulation claims tied to chlorella, and whether Genesis or Proudi publish feeding, palatability, or clinical data to support broader veterinary adoption. (efeedlink.com)
Australian algae producer Genesis Group is making a formal push into pet nutrition through a merger with Brisbane-based pet food company Proudi, a move that could widen retail access to chlorella-supplemented products in Australia. Trade coverage published August 25, 2026, said the deal gives Genesis access to Proudi’s established consumer brands and retail footprint, including Coles, Petbarn, and Pet Circle, while positioning the combined company to expand algae-based formulations across the pet food line. (efeedlink.com)
The transaction fits a broader pattern in companion animal nutrition: alternative ingredients once framed mainly around sustainability are now being marketed for functional health benefits, too. Reviews published in 2025 and 2026 describe growing interest in microalgae and seaweed as sources of protein, omega-3 fatty acids, micronutrients, prebiotics, and other bioactive compounds for dogs and cats. At the same time, those same reviews stress that the research base in companion animals is still relatively thin, especially compared with the speed of commercial innovation. (sciencedirect.com)
Key deal details suggest Genesis is not treating pet food as a side channel. Coverage of the merger said the combined business expects to roughly double revenue, with Proudi’s YumGuard range already using Australian-grown chlorella and the broader Proudi portfolio expected to incorporate the ingredient over time. Additional reporting said Proudi had secured a national distribution agreement with Coles, with products expected on shelves within weeks, and that international sales growth, including in Asian markets, is part of the expansion thesis. (efeedlink.com)
Company leadership is framing the move as a platform play rather than a single-product launch. In trade reporting, Genesis CEO Eric Chen said the strategy is to build premium nutrition businesses around shared science, manufacturing, and intellectual property, while Proudi founder Dennis King linked the deal to rising consumer expectations for pet food quality. That messaging aligns with what the literature shows: pet parents are increasingly responsive to products positioned around preventive health, ingredient quality, and environmental sustainability. (vegconomist.com)
Still, the science behind algae in pet diets is more nuanced than the marketing language often suggests. A Frontiers in Veterinary Science study found that adding spray-dried microalgae, including Chlorella vulgaris, at 0.5% to 1.5% did not materially change nutrient digestibility, food intake, or fecal output in healthy adult dogs, although broader algae research points to potential functional effects depending on species, dose, and processing. Other recent reviews note that algae ingredients may support sustainability and offer useful nutrients, but they also highlight open questions around palatability, optimal inclusion levels, processing methods that improve digestibility, and the lack of robust cat-specific trials. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, this merger is less about one Australian corporate deal and more about where the premium pet food market is heading. As algae-derived ingredients move into mainstream retail, clinicians can expect more questions from pet parents about chlorella, algae oils, and “functional” superfood claims. That raises practical issues around evidence standards, label scrutiny, nutrient adequacy, and whether a product’s implied health benefits are supported by feeding trials rather than ingredient theory alone. In particular, veterinarians may want to distinguish between complete-and-balanced formulations, supplements, and wellness-positioned products that make broader digestive or immune claims than the current evidence comfortably supports. (vegconomist.com)
There’s also a commercial signal here for the wider industry. Genesis is joining a growing group of companies trying to commercialize algae in companion animal nutrition, whether as omega-3 alternatives, protein inputs, or branded functional additives. If the Coles rollout succeeds, it could encourage more ingredient manufacturers to seek downstream control through branded pet food, rather than supplying business-to-business only. (vegconomist.com)
What to watch: Near term, watch for exact product claims, retail timing, and whether Genesis and Proudi release formulation specifics or feeding data as Coles distribution ramps. Longer term, the bigger question is whether algae-backed products can build veterinary credibility through published digestibility, safety, palatability, and clinical outcome data, especially in cats, where the evidence gap remains more pronounced. (efeedlink.com)